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E-mail address: bckim@kangwon.ac.kr (B.-C. Kim).Smad6, one of the inhibitory Smads, plays an important role in transforming growth factor-beta1
(TGF-b1)-mediated negative regulation of pro-inﬂammatory signaling. In this study, we found that
bacterial endotoxin lipopolysaccharide (LPS) inhibits TGF-b1-induced expression of Smad6 in
RAW264.7 cells. This repression was accompanied by increased Smad3 linker phosphorylation at
Thr-179 and Ser-208 and was dependent on ERK1/2 activity via the TLR4–IRAK1-linked signaling cas-
cade. The expression of a mutant Smad3, that lacks the phosphorylation sites in the linker regions,
signiﬁcantly reversed the inhibitory effect of LPS on TGF-b1-induced Smad6 expression and its anti-
inﬂammatory capacity. Collectively, our ﬁndings show how LPS pro-inﬂammatory signal antago-
nizes the anti-inﬂammatory activity of TGF-b1.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Inﬂammation is a local, protective response to many patholog-
ical conditions [1–3]. The successful resolution of microbial infec-
tion in mammals initially requires an innate immune response
that involves the synthesis and action of pro-inﬂammatory media-
tors such as cytokines and chemokines, as well as molecules with
antimicrobial activities. While the protective innate immune re-
sponse is indispensable, the pro-inﬂammatory response should
be intrinsically controlled to prevent excessive inﬂammation that
may have deleterious consequences for the affected organism. In
most cases, the innate immune response is initiated by a set of
the toll-like receptors (TLRs) [4–6]. Upon activation, TLRs transmit
the signals through adapter proteins such as the conserved mye-
loid differentiation factor 88 (MyD88) to activate interleukin-1
receptor activated kinases (IRAKs), transforming growth factor-b
(TGF-b)-activated kinase 1 (TAK1), IjB kinase (IKK), and mitogen
activated kinases (MAPKs). These intracellular kinases lead to acti-
vation of target genes including pro-inﬂammatory cytokines,
resulting in the induction of potent innate immune responses.chemical Societies. Published by E
chemistry, College of Natural
2-dong, Chuncheon 200-701,TGF-b1, one of three isoforms in mammals, is an anti-inﬂamma-
tory cytokine with potent immunoregulatory properties, predomi-
nantly secreted by immune cells [7–10]. Mice deﬁcient in TGF-b1
or transgenic mice whose T cells are unable to response to TGF-b
develop an autoimmune inﬂammatory disease [11,12], indicating
that TGF-b signaling is essential for maintenance of immune
homeostasis. TGF-b1 also negatively regulates activation and pro-
liferation of multiple types of immune cells and inhibits produc-
tion of pro-inﬂammatory cytokines such as interleukine-2 (IL-2),
IL-4, IL-7 and interferon-gamma (IFN-c) by inducing Foxp3, a mas-
ter regulator of regulatory T cells in naïve T cells, through the
Smad2/3 pathway [13]. Recently, Lee and co-workers [14] reported
that TGF-b1-induced Smad6 inhibits MyD88-dependent TLR sig-
naling pathways through direct binding with the adaptor protein
Pellino-1, and, thus acts as a mediator of TGF-b1-induced anti-
inﬂammatory activity, implying a critical role for TGF-b1 in the
taming of the innate immune response. Therefore, inactivation of
the anti-inﬂammatory TGF-b1 signaling may lead to pathological
situations, such as chronic inﬂammation and autoimmune disease.
The molecular mechanisms by which TGF-b1 inhibits the pro-
duction of pro-inﬂammatory mediators have been extensively
studied [14–16]. In contrast, little is known about the molecular
mechanisms involved in the negative regulation of anti-inﬂamma-
tory TGF-b1 signaling by pro-inﬂammatory signals. Lipopolysac-
charide (LPS), a surface component of gram-negative bacteria,lsevier B.V. All rights reserved.
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in macrophages by activating TLR4. In this study, we investigated
the molecular mechanism by which LPS inhibits TGF-b1 signaling
pathway leading to the anti-inﬂammatory Smad6 expression.
2. Materials and methods
2.1. Cell culture and establishments of stable cell lines expressing
Smad3 (EPSM) gene
RAW264.7, a mouse macrophage cell line, was obtained from
American Type Culture Collection (Manassas, VA). The cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented
with 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 lg/ml streptomycin. Generation of
the RAW264.7-Smad3 (EPSM) stable cell line was performed as
previously described [17]. RAW264.7 cells stably expressing the
Smad3 (EPSM) gene were initially screened for resistance to neo-
mycin, and veriﬁed through RT-PCR analysis.
2.2. Plasmids, DNA transfection and luciferase assay
Expression vectors encoding pcDNA3-MEK1AA, a dominant-
negative form of MEK1, and pcDNA3-SEK1KR, a kinase-deﬁcient
form of SEK1, were kindly provided by Dr. J.S. Gutkind (National
Institutes of Health). The pCMV-Smad3EPSM was a gift from
Dr. Fang Liu (The State University of New Jersey, USA). The plasmid
pSmad6-Luc was obtained from Dr. Seok-Hee Park (Sungkyunkwan
University, Korea). The RAW264.7 cells were transfected using Fu-
gene 6 (Roche, Mannheim, Germany). To control variations in cell
numbers and transfection efﬁciency, all clones were cotransfected
with 0.2 lg of CMV-b-GAL, a eukaryotic expression vector in which
Escherichia coli b-galactosidase (Lac Z) structural gene is under the
transcriptional control of the CMV promoter. Luciferase reporter
activity was assessed on a luminometer with a luciferase assay sys-
tem (Promega, Madison, WI) according to the manufacturer’s pro-
tocol. Transfection experiments were performed in duplicate with
two independently isolated sets, and these results were averaged.
2.3. Reagents, antibodies, and immunoblot analysis
Recombinant TGF-b1 was purchased from R&D systems (Min-
neapolis, MA). LPS was purchased from Sigma Chemical Co.
(St. Louis, MI). The followings were obtained from Calbiochem
(La Jolla, CA): U0126, a MAPK kinase inhibitor, SB203580, a p38
kinase inhibitor, SP600125, a JNK1/2 inhibitor. Small interfering
RNAs for control, mouse TLR4, mouse IRAK1, and mouse Smad2/3
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against the Myc epitope, IjB-b, and b-actin were
purchased from Santa Cruz Biotechnology. Antibodies against the
phosphor-Smad3 (Ser423/425), phosphor-ERK1/2, phosphor-JNK1/2,
and phosphor-p38 were obtained from Cell Signaling Technology
(Beverly, MA). Antibodies against the iNOS and Smad3 were
purchased from Transduction Laboratories (Lexington, KY) and
Upstate Cell Signaling (Charlottesville, VA). Smad3 phosphopeptide
antibodies against Ser208 and Thr179 were kindly provided by Dr.
Fang Liu (The State University of New Jersey, USA). Immunoblot
analysis was done as described [17].
2.4. RNA isolation and reverse transcriptase-polymerization chain
reaction (RT-PCR)
Total RNA was extracted using the phenol–guanidinium isothi-
ocyanate method [18]. RT-PCR was performed by Acess RT-PCR
system (Promega, Madison, WI) according to the manufacturer’sinstructions using the following mouse smad6 speciﬁc primers:
forward, 50-CTC AAC AAC CAC AGA TAG CA-30, and reverse, 50-
GTG CGT CTT TGT TAT TTC TC-30, mouse TLR4 primers: forward,
50-CCA TCG GTT GAT CTT GGG AGA A-30, and reverse, 50-TGC CAG
AGA CAT TGC AGA AAC A-30 and mouse iNOS primers: forward,
50-AAT GGC AAC ATC AGG TCG GCC ATC ACT-30, and reverse,
50-GCT GTG TGT CAC AGA AGT CTC GAA CTC-30 and mouse IL-1b
primer: forward, 50-ATG GCA ACT GTT CCT GAA CTC AAC T-30,
and reverse, 50-CAG GAC AGG TAT AGA TTC TTT CCT TT-30 and
mouse IRAK1 primers: forward, 50-CCT TCA GAG AGG CTA GCT
GTA CC-30, and reverse, 50-ACT TTG ACC TCT GAG TCT GAG GG-30
and mouse IL-6 primers: forward, 50-GAT AGT CAA TTC CAG AAA
CCG CTA-30, and reverse, 50-TAC TCC AGG TAG CTA TGG TAC
TCC-30 and mouse smad2 primers: 50-GTC ACC ATA CCA AGC ACT
TGC TC-30, and reverse, 50-CTG GAA TGG AGT GGG TGT AGT
CA-30 and mouse smad3 primers: forward, 50-AGT GCA TTA CCA
TCC CCA GG-30 and reverse, 50-AGG AGG TGG GGT TTC TGG AA-30
and mouse b-actin was ampliﬁed as a control, using the following
primers: forward, 50-ACG TTG CTA TCC AGG CTG TG-30, reverse,
50-GCG ACG TAG CAC AGC TTC TC-30. PCR ampliﬁed bands were
visualized on 1% agarose gels stained with ethidium bromide using
BioDoc-ItTM system (Ultraviolet Products, Upland, CA).
2.5. Indirect immunoﬂuorescence
RAW264.7 cells (1  105 cells) were plated onto 18-mm glass
coverslips 24 h prior to treatment with TGF-b1 for 30 min. The cov-
erslips were ﬁxed in cold 3.5% paraformaldehyde for 5 min, perme-
abilized in cold methanol for 2 min, and incubated for 5 min in
50 mM glycine to quench paraformaldehyde autoﬂuorescence,
and incubated for 2 h at room temperature with anti-phospho-
Smad3 (Ser-208). After washing in phosphate-buffered saline
(PBS), the coverslips were incubated for 1 h at room temperature
with Alexa488-conjugated goat anti-rabbit IgG antibody (Molecular
Probes, Eugene, OR). The coverslips were then mounted in medium
containing 4,6-diamino-2-phenylindole (DAPI) (h-1200; Vector
Laboratories, Burlingame, CA), and then visualized using an
Olympus Fluoview-FV300 confocal microscope.
2.6. Statistical analysis
All data presented are expressed as means ± S.D., and a repre-
sentative of three or more independent experiments. Statistical
analyses were by Student’s t-test for paired data. Results were con-
sidered signiﬁcant at P < 0.05.
3. Results and discussion
3.1. LPS inhibits TGF-b1-mediated induction of Smad6 expression in a
TLR4, IRAK1, and ERK1/2-dependent manner
Because Smad6 has been previously reported to be a key medi-
ator of anti-inﬂammatory TGF-b1 signal in macrophages [14], we
assessed whether LPS inhibits TGF-b1-induced Smad6 expression
in RAW264.7 cells. RT-PCR analysis showed that LPS inhibits the
TGF-b1-induced Smad6 expression in a dose-dependent manner
(Fig. 1A). This effect was evident at concentrations of LPS as low
as 5 ng/ml. RAW264.7 cells challenged with TGF-b1 at various peri-
ods after LPS treatment also showed dramatic attenuation of
Smad6 expression when compared to cells treated with TGF-b1
only (Fig. 1B). This inhibitory effect of LPS on Smad6 gene expres-
sion was observed early (1 h) after TGF-b1 treatment in RAW264.7
cells. Consistent with these results, TGF-b1-induced Smad6 promoter
activation also was dose- (Fig. 1C) and time- (Fig. 1D) dependently
abolished in cells pretreated with LPS. Notably, LPS-mediated
Fig. 1. LPS inhibits TGF-b1-induced Smad6 expression in RAW264.7 cells. (A) Cells were pretreated with LPS at the indicated amounts for 30 min, and then incubated with
TGF-b1 (5 ng/ml) for 6 h. (B) Cells were preincubated with LPS (5 ng/ml) for 30 min before stimulation with TGF-b1 (5 ng/ml) for the indicated times. Expression of Smad6
mRNA were monitored by RT-PCR analysis. Expression of b-actin mRNA was used as loading control. Cells were transiently transfected with mouse Smad6 promoter-reporter
construct (pSmad6-Luc). After transfection, cells were preincubated with LPS at the indicated amounts for 30 min before stimulation with TGF-b1 (5 ng/ml) for 24 h (C) or
pretreated with LPS (5 ng/ml) for 30 min before exposed to TGF-b1 (5 ng/ml) for the indicated periods (D). Luciferase activities were normalized on the basis of
b-galactosidase expression to adjust for variation in transfection efﬁciency. Bars depict the means ± S.D. of three independent experiments.
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by cyclohexamide (Supplementary Fig. 1), indicating that new
protein synthesis does not required for the inhibition by LPS.
Because LPS transmit its pro-inﬂammatory signal via TLR4, we
determined whether TLR4 signaling is responsible for the inhibi-
tion of Smad6 gene expression by LPS treatment. As shown in
Fig. 2A, inhibition of TGF-b1-induced Smad6 expression by LPS
treatment was substantially reduced by transfection of small inter-
fering RNA (siRNA) speciﬁc for TLR4, but not by scrambled siRNA.
In agreement with this result, the involvement of the IRAK1 kinase,
a key mediator of TLR4 signaling pathway [4], in the action of LPS
was also conﬁrmed using a IRAK1 siRNA, which signiﬁcantly
blocked LPS-mediated inhibition of TGF-b1-induced Smad6
expression (Fig. 2B) and Smad6 promoter activity (Fig. 2C). We
next investigated whether signal mechanisms involving mitogen-
activated protein kinases (MAPKs) are responsible for the negative
regulation of Smad6 expression by LPS. Pretreatment with U0126,
an inhibitor of MAPK kinase 1 (MEK1), or transfection of cells with
dominant-negative form of MEK1, pCDNA3-MEK1AA, all markedly
reversed the inhibitory effect of LPS on Smad6 expression (Fig. 2D)
or Smad6 promoter activity (Fig. 2E). On the other hand, pretreat-
ment with SP600125, a c-Jun NH2-terminal kinase (JNK) inhibitor,
or transfection of cells with kinase-deﬁcient form of SEK1,
pCDNA3-SEK1KR, had no signiﬁcant effect on the inhibition of
Smad6 expression by LPS treatment. These results indicate that
the decrease in expression of TGF-b1-mediated Smad6 gene in-
duced by LPS is mediated by TLR4 signaling pathway involving
IRAK1 and ERK1/2 in macrophages.
3.2. The Smad pathway is required for the induction of Smad6
expression and suppression of IL-6 and IL-1b expression induced by
TGF-b1
Although Smad6 has been reported to be an important mediator
of the anti-inﬂammatory TGF-b1 signal [14], the signaling mecha-
nism by which TGF-b1 induces expression of Smad6 remains to be
characterized. It is commonly accepted that TGF-b1 transmits sig-
nal into cells through the Smad-dependent pathway and Smad-
independent MAPK pathway [19]. We preferentially determined
whether MAPK signal mechanism is responsible for the up-regula-
tion of Smad6 gene expression by TGF-b1 in macrophages. As
shown in Fig. 3A, TGF-b1-mediated increase in Smad6 mRNA level
was not signiﬁcantly affected by pretreatment with U0126, a speciﬁcinhibitor of MEK1, SB203580, a speciﬁc inhibitor of p38 kinase, or
SP600125, a speciﬁc inhibitor of JNK1/2, at similar concentrations.
In contrast, knock-down of Smad2 and Smad3 gene expression
using a siRNA speciﬁc for both Smad2 and Smad3 effectively
blocked the expression of Smad6 induced by TGF-b1 (Fig. 3B). In
addition, TGF-b1-mediated suppression of LPS-induced IL-1b and
IL-6 expression was markedly attenuated in Smad2/Smad3 double
knock-down cells (Fig. 3C). These results indicate that the Smad-
dependent pathway plays a major role in mediating the induction
of Smad6 gene in response to TGF-b1, thus contributing to its anti-
inﬂammatory effect.
3.3. LPS induces Smad3 linker phosphorylation through the TLR4–
IRAK1–ERK1/2 pathway and inhibits Smad transcriptional activity
A major event leading to Smad3 activation is the TGF-b1-in-
duced, TGF-b receptor I (TbRI)-mediated phosphorylation of Smad3
at two C-terminal Ser residues, Ser-423 and Ser-425, which trig-
gers dissociation of Smad3 from TbRI receptor to form complex
with Smad4, accumulates into the nucleus and transactivates tar-
get genes [7]. On the other hand, a growing body of evidences re-
vealed that the phosphorylation of Smad3 linker region connecting
conserved two MH1 and MH2 domains by different signaling ki-
nases antagonizes its function as a key transducer of TGF-b1 signal-
ing [20–22]. We thus assessed the ability of LPS to induce
phosphorylation of Smad3. Treatment with LPS (10 ng/ml) resulted
in phosphorylation of Smad3 at Thr-179 and Ser-208, but not of
Smad3 at Ser-423 and Ser-425 of C-terminus (Fig. 4A). Smad3
phosphorylation at Ser-208 reached a peak at 30 min and then de-
clined into baseline at 12 h. In situ immunostaining analysis also
showed that LPS increases phosphorylation of Smad3 at Ser-208,
with substantial levels of Smad3 staining remaining in the cyto-
plasm in most cells (Fig. 4B). We next determined whether TLR4
pathway is responsible for LPS-induced phosphorylation of Smad3.
Knocking down of TLR4 (Fig. 4C) or IRAK1 (Fig. 4D) expression re-
sulted in remarkable decrease of LPS-induced Smad3 linker phos-
phorylation. In addition, LPS-mediated increase in Smad3 linker
phosphorylation level was completely blocked by U0126, a speciﬁc
inhibitor of MEK1, whereas similar concentrations of SP600125, a
speciﬁc inhibitor of JNK or SB203580, a speciﬁc inhibitor of p38
MAPK, had no signiﬁcant effect (Fig. 4E). To further analyze the ef-
fect of LPS-induced Smad3 linker phosphorylation on Smad3 tran-
scriptional activity, a Smad3 mutant (Fig. 5A) lacking four
Fig. 2. TLR4, IRAK1, and ERK1/2 are required for the LPS-mediated inhibition of TGF-b1-induced Smad6 expression in RAW264.7 cells. Subconﬂuent cells transfected with
scramble control siRNA (siCon; A and B), TLR4 siRNA (siTLR4; A), or IRAK1 siRNA (siIRAK1; B) were incubated without or with LPS (5 ng/ml) for 30 min before challenge with
TGF-b1 (5 ng/ml) for 6 h. (C) Cells transfected with pSmad6-Luc were retransfected with siCon or siIRAK1. At 24 h after transfection, cells were pretreated with LPS (5 ng/ml)
for 30 min before exposed to TGF-b1 (5 ng/ml) for 24 h. Bars depict the means ± S.D. of three independent experiments. ⁄P < 0.05 compared with siCon-transfected cells
treated with LPS/TGF-b1. (D) Cells were incubated without or with LPS (5 ng/ml) for 30 min in the absence or presence of U0126 (10 lM) or SP600125 (15 lM), followed by
treatment without or with TGF-b1 (5 ng/ml) for additional 6 h. (E) Cells were cotransfected with pSmad6-Luc and pcDNA3, pcDNA3-MEK1AA (MEK1AA), or pcDNA3-SEK1KR
(SEK1KR). At 24 h after transfection, cells were pretreated with LPS (5 ng/ml) for 30 min before exposed to TGF-b1 (5 ng/ml) for 24 h. Bars depict the means ± S.D. of three
independent experiments. ⁄P < 0.05 compared with pcDNA3-transfected cells treated with LPS/TGF-b1. Expression of TLR4 (A), IRAK1 (B), and Smad6 (A, B, and D) mRNA were
monitored by RT-PCR analysis. Expression of b-actin mRNA was used as loading control. Luciferase activities were normalized on the basis of b-galactosidase expression to
adjust for variation in transfection efﬁciency (C and E).
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nase site mutant construct, Smad3EPSM) plasmid and Smad3-
responsive SBE-Luc reporter were co-transfected into RAW264.7
cells. LPS completely abolished TGF-b1-induced SBE-Luc reporter
activity and this effect was markedly attenuated by ectopically ex-
pressed Smad3EPSM (Supplementary Fig. 2A). These results indi-
cated that LPS directly suppress Smad3 transcriptional activity by
inducing Smad3 linker phosphorylation through the mediation of
TLR4 followed by IRAK1–ERK1/2 signaling in sequence.
3.4. Linker phosphorylation of Smad3 is critical for the LPS-mediated
inhibition of anti-inﬂammatory TGF-b1 signaling-induced Smad6
expression
We next determined if Smad3 linker phosphorylation is critical
for the LPS-mediated suppression of TGF-b1-induced Smad6
expression. Because phosphorylation of Smad3 linker region by
LPS was transient, we tested the effects of short-term and long-
term LPS exposure on Smad6 expression. RAW264.7 cells exposed
to LPS for 30 min exhibited a perfect decrease in TGF-b1-induced
Smad6 expression. On the other hand, the Smad6 induction was
not affected in cells pretreated with LPS for 12 and 24 h (Supple-
mentary Fig. 2B). To more directly analyze an effect of LPS phos-
phorylation of Smad3 on the Smad6 expression, we generated a
stable cell lines that expressing a Smad3EPSM mutant (Fig. 5A).The blockade of linker phosphorylation by highly expressed Sma-
d3EPSM perfectly inhibited the LPS ability to downregulate TGF-
b1-induced Smad6 expression (Fig. 5B) and TGF-b1-induced Smad6
promoter activity (Fig. 5C). Moreover, LPS-mediated inhibition of
TGF-b1 anti-inﬂammatory capacity to block pro-inﬂammatory
IL-6 expression was substantially reduced in RAW264.7pCMV-S3(EPSM)
cells compared with the RAW264.7
pCMV
control cells (Fig. 5D), sug-
gesting that Smad3 phosphorylation at Thr-179 and Ser-208 by
TLR4/IRAK1-activated ERK1/2 may be important for LPS-mediated
suppression of TGF-b1-induced Smad6 expression and its anti-
inﬂammatory activity in murine macrophages.
Under an endotoxin challenge, mutual suppression of signaling
between TGF-b and pro-inﬂammatory cytokines is necessary for
the balance of immunity and tolerance. The molecular mechanisms
by which TGF-b1 inhibits the production of pro-inﬂammatory
mediators have been extensively studied [15,16], whereas the
molecular mechanisms involved in the negative regulation of
anti-inﬂammatory TGF-b1 signaling by pro-inﬂammatory signals
are less understood. Smad6, one of inhibitory Smads, has been re-
cently elucidated as a key mediator in TGF-b-mediated anti-
inﬂammatory signaling pathway. The results of present study
show that LPS transcriptionally repress TGF-b1-induced Smad6
expression and this repression is accompanied by increased phos-
phorylation of Smad3 at linker regions and dependent on ERK1/2
activity via TLR4–IRAK1-linked signaling cascade (Fig. 6).
Fig. 3. Activation of Smad2 and Smad3 by TGF-b1 is required for the induction of Smad6 and inhibition of pro-inﬂammatory gene expression. (A) Cells were incubated
without or with LPS (5 ng/ml) for 30 min in the absence or presence of U0126 (10 lM), SB203580 (5 lM) or SP600125 (15 lM), followed by treatment without or with TGF-b1
(5 ng/ml) for additional 6 h. Cells were transfected with siCon or mixed Smad2 and Smad3 siRNAs (siS2/3). At 24 h after transfection, cells were exposed to TGF-b1 (5 ng/ml)
for 6 h (B) or pretreated with TGF-b1 (5 ng/ml) for 2 h before exposed to LPS (5 ng/ml) for 2 h (C). Expressions of Smad6 (A and B), Smad2 (B and C), IL-6 (C), and IL-1b (C)
mRNA were monitored by RT-PCR analysis and expression of endogenous Smad3 protein was observed by immunoblot analysis (B). Expression of b-actin was used as loading
control.
Fig. 4. LPS induces the phosphorylation of Smad3 at linker regions via a TLR4–IRAK1–ERK1/2 signaling pathway. (A) RAW264.7 cells were treated with LPS (5 ng/ml) for the
indicated periods. Smad3 phosphorylated at Ser-208, at Thr-179, or at Ser-423/425, iNOS, and b-actin was observed by immunoblot analysis. (B) Cells cultured on chamber
slide were incubated without or with LPS (5 ng/ml) for 30 min. Cells were then ﬁxed and immunostained for phosphor-Smad3 (Ser-208) (Alexa488; green). The nuclei were
stained with 4,6-diamidino-2-phenylindole (DAPI; blue). The merger of Alexa488 and DAPI is shown in the right panel. The images presented here are representative of
multiple ﬁelds from three independent experiments. Cells transfected with siCon (C and D), siTLR4 (C), or siIRAK1 (D) were incubated for 30 h and then treated with LPS (5 ng/
ml) for another 30 min. (E) Cells were treated with DMSO, U0126 (10 lM), SB203580 (5 lM) or SP600125 (15 lM) before stimulation without or with LPS (5 ng/ml) for
30 min. Whole cell lysates were analyzed for phosphor-Smad3 (Ser-208), phosphor-ERK1/2, phosphor-JNK1/2, phosphor-p38, IjBb, IRAK1, and b-actin by immunoblotting.
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Smad6 negatively regulates IL-1R/TLR signaling by disrupting
MyD88/IRAK1/Pellino1/TRAF6 signaling through direct binding
with the adaptor protein pellino1 [14]. However, the signaling
mechanism by which TGF-b1 induces expression of Smad6 remains
to be characterized. Our results demonstrated that Smad pathway,
but not non-Smad pathway, is critical for the TGF-b1-mediatedup-regulation of Smad6 and its anti-inﬂammatory activity. Previous
report that Tgfb1/ and Smad3/ mice show higher expression of
pro-inﬂammatory cytokines and increased NF-jB activation [23]
strongly support our ﬁnding.
The linker region of Smad3 (amino acids 143–230) physically
and functionally interacts with nuclear coactivators, such as the
histone acetyltransferases CBP/P300 and p/CAF and essential for
Fig. 5. Mutation of the linker phosphorylation sites in Smad3 decreases the ability of LPS to inhibit TGF-b1-induced Smad6 expression and its anti-inﬂammatory activity. (A)
Schematic representation of alternative phosphorylation sites in Smad3 and of mutation of these sites in EPSM. (B) Cells that were stably transfected with pCMV
(RAW264.7pCMV) or pCMV-Smad3EPSM (RAW264.7S3(EPSM)) were incubated for 24 h and then treated with LPS (5 ng/ml) for 30 min before exposed to TGF-b1 (5 ng/ml) for
6 h. Expression of Smad6, Smad3, and b-actin mRNA were monitored by RT-PCR analysis. Expression of b-actin was used as loading control. (C) Cells co-transfected with
mouse Smad6 promoter-reporter construct (pSmad6-Luc) and pCMV or pCMV-Smad3EPSM were incubated for 24 h and then treated with LPS (5 ng/ml) for 30 min before
exposed to TGF-b1 (5 ng/ml) for 24 h. Luciferase activities were normalized on the basis of b-galactosidase expression to adjust for variation in transfection efﬁciency. Bars
depict the means ± S.D. of three independent experiments. ⁄P < 0.05 compared with pCMV-transfected cells treated with LPS/TGF-b1. (D) RAW264.7pCMV cells or
RAW264.7S3(EPSM) cells were preincubated in the absence or presence of LPS (5 ng/ml) for 30 min. Then the cells were incubated without or with TGF-b1 (5 ng/ml) for 3 h
before stimulation with LPS (5 ng/ml) for additional 2 h. Expressions of IL-6, Smad6, Smad3, and b-actin mRNA were monitored by RT-PCR analysis.
Fig. 6. Schematic summary of results. Model represents reciprocal inhibition
mechanism by TGF-b1 and LPS. TGF-b1 activates Smad3 and then Smad3-target
gene Smad6 inhibits LPS-induced NF-jB activation. LPS overrides the inhibitory
effect of TGF-b1 on NF-jB activation by triggering Smad3 linker phosphorylation
via TLR4–IRAK1-activated ERK1/2 and subsequent blocking Smad6 expression.
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Smad3 linker region may inhibits the transactivation function of
Smad3 to induce Smad6 gene expression by inﬂuencing its interac-
tions with coactivators or auxiliary factors that bind to linker
region.
A number of evidences reveal that ERK1/2 is a key molecule of
inﬂammatory reactions triggered by pathogenic infection such as
Helicobacter pylori and Mycobacterium tuberculosis [24,25] and tar-
geting ERK signaling has therapeutic implications for inﬂammatory
disorders [26,27]. It is thus notable that Smad3 phosphorylation
at Thr-179 and Ser-208 by TLR4/IRAK1-activated ERK1/2 is respon-
sible for the negative regulation of Smad6 expression by LPS.
Consequently, Smad3 linker phosphorylation through TLR4–
IRAK1–ERK1/2-linked pro-inﬂammatory pathway represents a
straightforward mechanism by which LPS can attenuate anti-
inﬂammatory TGF-b1 function. Therefore, modulations of Smad3linker phosphorylation from excessive inﬂammation may be
important therapeutic strategies of inﬂammatory diseases. Our
ﬁndings for the ﬁrst time show how LPS inﬂammatory signal antag-
onizes the anti-inﬂammatory TGF-b1 in murine macrophages.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2011.01.044.
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